No Data
No Data
Gilead Sciences: A Cautious Hold Amidst Mixed Performance and Future Uncertainties
Is Gilead Sciences (NASDAQ:GILD) A Risky Investment?
About 73% of the S&P 500 Names Beat on EPS During the Week - Earnings Scorecard
12 Out of 17 Healthcare Companies Beat Profit Estimates This Week- Earnings Scorecard
Gilead Exits J&J Royalty Deal for Liver Drug Ahead of Potential FDA Nod
Express News | RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $72
No Data